neuropeptide-Y and somatostatin neurons in hypophysectomized rats.
Endocrinology 135:2765–2771.
Lai Z, Emtner M, Roos P, Nyberg F (1991) Characterization of putative
growth hormone receptors in human choroid plexus. Brain Res
546:222–226.
Landgraf R, Gerstberger R, Montkowski Probst JC, Wotjak CT, Holsboer
F, Engelmann M (1995) V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. J Neurosci
15:4250 – 4258.
Lanzi R, Tannenbaum GS (1992) Time course and mechanism of growth
hormone's negative feedback effect on its own spontaneous release.
Endocrinology 130:780 –788.
Linfoot JA, Garcia JF, Wei W, Fink R, Sarin R, Born JL, Lawrence JH
(1970) Human growth hormone levels in the cerebrospinal fluid. J Clin
Endocrinol Metab 31:230 –232.
Lobie PE, Garcia-Aragon J, Lincoln DT, Barnard R, Wilcox JN, Waters
MJ (1993) Localization and ontogeny of growth hormone receptor
gene expression in the central nervous system. Dev Brain Res
74:225–233.
Miki N, Ono M, Miyoshi H, Tsushima T, Shizume K (1989) Hypothalamic growth hormone releasing factor (GRF) participates in the negative feedback regulation of growth hormone secretion. Life Sci
44:469 – 476.
Minami S, Kamegai J, Hasegawa O, Sugihara H, Okada K, Wakabayashi
I (1993) Expression of growth hormone receptor gene in rat hypothalamus. J Neuroendocrinol 5:691– 696.
Oliver C, Mical RS, Porter JC (1977) Hypothalamic-pituitary vasculature: evidence for retrograde blood flow in the pituitary stalk. Endocrinology 101:598 – 604.
Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates.
London: Academic.
Rogers KV, Vician L, Steiner RA, Clifton DK (1988) The effect of
hypophysectomy and growth hormone administration on preprosomatostatin messenger ribonucleic acid in the periventricular nu- cleus of the rat hypothalamus. Endocrinology 122:586 –591.
Sakai RR, He PF, Yang XD, Ma LY, Guo YF, Reilly JJ, Moga CN,
Fluharty SJ (1994) Intracerebroventricular administration of AT (1)
receptor antisense oligonucleotides inhibits the behavioral actions of
angiotensin II. J Neurochem 62:2053–2056.
Tannenbaum GS (1980) Evidence for autoregulation of growth hormone
secretion via the CNS. Endocrinology 107:2117–2120.
Tannenbaum GS, Ling N (1984) The interrelationships of growth hormone (GH)-releasing factor and somatostatin in generation of the
ultradian rhythm of GH secretion. Endocrinology 115:1952–1957.
Tannenbaum GS, Martin JB (1976) Evidence for an endogenous ultradian rhythm governing growth hormone secretion in the rat. Endocrinology 98:562–570.
Veldhuis JD, Carlson ML, Johnson ML (1987) The pituitary secretes in
bursts: appraising the nature of glandular secretory impulses by simultaneous multiple parameter deconvulsion of plasma hormone concentrations. Proc Natl Acad Sci USA 84:7686 –7690.
Wahlestedt C, Golanov E, Yamamoto S, Yee F, Ericson H, Yoo H,
Inturrisi CE, Reis DJ (1993a) Antisense oligodeoxynucleotides to
NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions. Nature 363:260 –263.
Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M (1993b) Modulation
of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides. Science 259:528 –531.
Willoughby JO, Menadue M, Zeegers P, Wise PH, Oliver JR (1980)
Effects of human growth hormone on the secretion of rat growth
hormone. J Endocrinol 86:165–169.
Zhou LW, Zhang SP, Qin ZH, Weiss B (1994) In vivo administration of
an oligodeoxynucleotide antisense to the D2 dopamine receptor messenger RNA inhibits D2 dopamine receptor-mediated behavior and the
expression of D2 dopamine receptors in mouse striatum. J Pharmacol
Exp Ther 268:1015–1023.
